Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/11/2011

inical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo:  http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
2. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
3. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
4. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
9. Ardea Biosciences to Present at Two Upcoming Investor Conferences
10. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
11. Ardea Biosciences Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Madison, WI (PRWEB) May 24, 2013 ... to the discovery and development of calcium-binding proteins ... publication of safety assessment study of apoaequorin ... an international journal published for the British Industrial ... the study was to investigate potential adverse effects, ...
(Date:5/23/2013)... May 23, 2013 Can economic incentives ... work motivate members of the public to increase their ... Johns Hopkins Carey Business School Assistant Professor ... Pointing to a large body of recent research that ... May 24, 2013, issue of Science that the World ...
(Date:5/23/2013)... The maker community is a contemporary ... They focus on learning practical skills while applying them ... bringing their ideas to life via crowdfunding. A subgroup ... making projects using biology. Glowing Plant has worked for ... them glow with bioluminescence genes, and has now pursued ...
(Date:5/23/2013)... , May 23, 2013 BioTrends Research ... advisory firms for specialized biopharmaceutical issues, finds that, ... infectious disease specialists reported that in the past ... intentionally delaying treatment) in anticipation of the next ... months ago, when only 6 percent reported that ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... Colo., Feb. 1 Taligen Therapeutics, Inc. today,announced ... a tranched Series B,financing. The financing was led ... existing investors, including Sanderling Ventures, Tango,and High Country ... only an infusion of capital but the,addition of ...
... Therapeutics (Amex:,CXM) announced that it has completed ... and other accredited or qualified investors,that was ... Asset Management,Company acted as the sole placement ... http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ), The securities were offered ...
... DIEGO, Jan. 31 Cadence Pharmaceuticals,Inc. (Nasdaq: ... on in-licensing,developing and commercializing proprietary product candidates ... today that the company,s,President and CEO Theodore ... February 5, 2008 at 4:00 pm Eastern ...
Cached Biology Technology:Taligen Therapeutics Secures Series B Financing 2Cardium Completes $5.3 Million Registered Direct Offering 2Cardium Completes $5.3 Million Registered Direct Offering 3Cardium Completes $5.3 Million Registered Direct Offering 4Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York 2
(Date:5/22/2013)... a novel technique that can detect molecular variants in ... one of the most important, though time-consuming, processes in ... in Nature , post-doctoral researcher David Patterson, Professor ... the Center for Free-Electron Laser Science (CFEL) in Hamburg, ... fields to identify molecular variants apart, and to determine ...
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
(Date:5/22/2013)... bacteria is responsible for legionellosis, an infectious disease ... us, this pathogen has developed a complex method enabling ... cells, thus avoiding these acting against the infectious bacteria. ... CIC bioGUNE, in which teams from the National Institute ... Supercomputation Centre in Barcelona (BSC) have also participated, has ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3Mechanism discovered which aids Legionella to camouflage itself in the organism 2
... of mechanism causing cancer susceptibility, showing that tiny changes ... attract modifying "biochemical tags", effectively switching them off and ... The study and its findings are reported in ... The researchers, from the University of New South Wales ...
... with environmental threats like bad weather, predators or oil ... researchers have analyzed blood samples to detect corticosterone levels ... have shown that corticosterone spikes can also be detected ... in the May 11 online edition of " Journal ...
... Institute of General Medical Sciences, part of the National ... of Infectious Disease Agent Study for a research project ... by Stephen Eubank, professor. Infectious diseases pose one ... The Models of Infectious Disease Agent Study (MIDAS) is ...
Cached Biology News:'Methyl magnet' genes can cause family cancer risk 2A tool to measure stress hormone in birds -- feathers 2National Institutes of Health renews successful infectious disease research study 2National Institutes of Health renews successful infectious disease research study 3